Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01655316
  4. Details
NCT01655316 Clinical Trial

Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

Paroxysmal Supraventricular Tachycardia Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01655316
Other study ID # 16062
Secondary ID
Status Completed
Phase Phase 4
First received July 30, 2012
Last updated November 12, 2012
Start date October 2010
Est. completion date August 2011

Study information
Verified date November 2012
Source Tehran University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ministry of Health
Study type Interventional

Clinical Trial Summary

PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases.

Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent.

Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising.

This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.

Recruitment information / eligibility
Status Completed
Enrollment 90
Est. completion date August 2011
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age>18 years old

- PSVT on emergency department presentation

Exclusion Criteria:

- Instability in hemodynamic status

- Allergy to Verapamil

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Verapamil

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Tehran University of Medical Sciences

Outcome
Type Measure Description Time frame Safety issue
Primary Recurrence Control 2 hours No
See also
  Status Clinical Trial Phase
Completed NCT04072835 - Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 Phase 3
Completed NCT05770921 - Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia（PSVT） N/A
Active, not recruiting NCT05820035 - A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia N/A
Not yet recruiting NCT06327425 - MCG for Localization of Tachyarrhythmia's Origin N/A
Recruiting NCT05410860 - Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia Phase 3
Completed NCT03464019 - Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxymal Supraventricular Tachycardia (PSVT). NODE 301 [Part 1 and Part 2 (RAPID Study)] Phase 3
Completed NCT03042078 - Zero-fluoroscopy Approach Versus Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia N/A
Completed NCT04215640 - Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes N/A
Completed NCT03348436 - Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation N/A
Enrolling by invitation NCT04952610 - Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia Phase 3
Recruiting NCT05763953 - The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Phase 2
Terminated NCT03635996 - Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 Phase 3